Literature DB >> 29787418

Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis.

Karn Wijarnpreecha1, Charat Thongprayoon1, Boonphiphop Boonpheng2, Panadeekarn Panjawatanan3, Konika Sharma1, Patompong Ungprasert4, Surakit Pungpapong5, Wisit Cheungpasitporn6.   

Abstract

BACKGROUND/
OBJECTIVES: The relationship between nonalcoholic fatty liver disease (NAFLD) and albuminuria has been shown in many epidemiologic studies, although the results were inconsistent. This meta-analysis was conducted to summarize all available data and to estimate the risk of albuminuria among patients with NAFLD.
METHODS: Comprehensive literature review was conducted utilizing Medline and Embase database through January 2018 to identify studies that compared the risk of albuminuria among patients with NAFLD versus those without NAFLD. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
RESULTS: Nineteen studies (17 cross-sectional studies and two cohort studies) with 24 804 participants fulfilled the eligibility criteria and were included in this meta-analysis. The risk of albuminuria among patients with NAFLD was significantly higher than those without NAFLD with the pooled odds ratio (OR) of 1.67 [95% confidence interval (CI): 1.32-2.11]. Subgroup analysis demonstrated the significantly increased risk of albuminuria among patients with NAFLD without diabetes with pooled OR of 2.25 (95% CI: 1.65-3.06). However, we found no significant association between albuminuria and NAFLD among diabetic patients [pooled OR 1.28 (95% CI: 0.94-1.75)].
CONCLUSION: A significantly increased risk of albuminuria among patients with NAFLD was observed in this meta-analysis. Physicians should pay more attention to the early detection and subsequent treatment of individuals with microalbuminuria especially in patients with NAFLD.

Entities:  

Mesh:

Year:  2018        PMID: 29787418     DOI: 10.1097/MEG.0000000000001169

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  11 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

2.  Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses.

Authors:  Lixian Zhong; Chutian Wu; Yuting Li; Qiuting Zeng; Leizhen Lai; Sisi Chen; Shaohui Tang
Journal:  Ther Adv Chronic Dis       Date:  2022-05-19       Impact factor: 4.970

3.  Increased end-stage renal disease risk in patients with inflammatory bowel disease: A nationwide population-based study.

Authors:  Seona Park; Jaeyoung Chun; Kyung-Do Han; Hosim Soh; Kookhwan Choi; Ji Hye Kim; Jooyoung Lee; Changhyun Lee; Jong Pil Im; Joo Sung Kim
Journal:  World J Gastroenterol       Date:  2018-11-14       Impact factor: 5.742

Review 4.  Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?

Authors:  Yoshio Sumida; Masashi Yoneda; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Hideki Hayashi; Yoichi Nishigaki; Yusuke Suzuki; Takafumi Naiki; Asahiro Morishita; Hiroshi Tobita; Shuichi Sato; Naoto Kawabe; Shinya Fukunishi; Tadashi Ikegami; Takaomi Kessoku; Yuji Ogawa; Yasushi Honda; Takashi Nakahara; Kensuke Munekage; Tsunehiro Ochi; Koji Sawada; Atsushi Takahashi; Taeang Arai; Tomomi Kogiso; Satoshi Kimoto; Kengo Tomita; Kazuo Notsumata; Michihiro Nonaka; Kazuhito Kawata; Taro Takami; Takashi Kumada; Eiichi Tomita; Takeshi Okanoue; Atsushi Nakajima
Journal:  Int J Mol Sci       Date:  2020-07-13       Impact factor: 5.923

5.  Energy Expenditure Improved Risk Factors Associated with Renal Function Loss in NAFLD and MetS Patients.

Authors:  Manuela Abbate; Catalina M Mascaró; Sofía Montemayor; María Barbería-Latasa; Miguel Casares; Cristina Gómez; Escarlata Angullo-Martinez; Silvia Tejada; Itziar Abete; Maria Angeles Zulet; Antoni Sureda; J Alfredo Martínez; Josep A Tur
Journal:  Nutrients       Date:  2021-02-15       Impact factor: 5.717

6.  Systemic Immune-Inflammation Index Is Associated With Increased Urinary Albumin Excretion: A Population-Based Study.

Authors:  Zheng Qin; Hancong Li; Liya Wang; Jiwen Geng; Qinbo Yang; Baihai Su; Ruoxi Liao
Journal:  Front Immunol       Date:  2022-03-21       Impact factor: 7.561

Review 7.  Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?

Authors:  Carolina M Perdomo; Nuria Garcia-Fernandez; Javier Escalada
Journal:  J Clin Med       Date:  2021-05-10       Impact factor: 4.241

8.  Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study.

Authors:  Xiaoming Li; Mingfeng Xia; Hui Ma; Yu Hu; Hongmei Yan; Wanyuan He; Huandong Lin; Nai Qing Zhao; Jian Gao; Xin Gao
Journal:  BMJ Open       Date:  2021-06-29       Impact factor: 2.692

9.  Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes.

Authors:  Eugene Han; Yongin Cho; Kyung-Won Kim; Yong-Ho Lee; Eun Seok Kang; Bong-Soo Cha; Byung-Wan Lee
Journal:  Medicine (Baltimore)       Date:  2020-08-14       Impact factor: 1.817

10.  Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus.

Authors:  Hae Kyung Kim; Minyoung Lee; Yong-Ho Lee; Eun Seok Kang; Bong-Soo Cha; Byung-Wan Lee
Journal:  Diabetes Metab J       Date:  2021-07-13       Impact factor: 5.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.